2023 annual financial data
Avalo Therapeutics 2023 Operating margin
Direct answer
Operating margin was -1,421.57%.
Operating income was -27,351,000 USD and net income was -31,544,000 USD.
Operating cash flow was -30,680,000 USD.
Get free Avalo Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,924,000 USD
- Operating income
- -27,351,000 USD
- Net income
- -31,544,000 USD
- Operating cash flow
- -30,680,000 USD